Skip to main content
SpringerLink
Log in

A Novel Dendritic Cell-Based Vaccination Protocol to Stimulate Immunosurveillance of Aggressive Cancers

  • Protocol
  • First Online:
Cancer Immunosurveillance

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1884))

Abstract

A major challenge in the development of a successful tumor vaccination is to break immune tolerance and to sensitize efficiently the immune system toward relevant tumor antigens, thus enabling T-cell-mediated antitumor responses in vivo. Dendritic cell (DC)-based immunotherapy shows the advantage to induce an adaptive immune response against the tumor, with the potential to generate a long-lasting immunological memory able to prevent further relapses and hopefully metastasis. Recently different preclinical studies highlighted the golden opportunity to exploit the features of immunogenic cell death (ICD) to generate ex vivo a highly immunogenic tumor cell lysate as potent antigen formulation for improved DC-based vaccine against aggressive cancers. This chapter focuses on the methods to obtain tumor lysates from cells undergoing ICD to be used for DC pulsing and to test the functionality of the generated DCs for antitumor vaccine development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P (2015) Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol 6:588. https://doi.org/10.3389/fimmu.2015.00588

    Article  PubMed  PubMed Central  Google Scholar 

  2. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54–61. https://doi.org/10.1038/nm1523

    Article  CAS  PubMed  Google Scholar 

  3. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G (2008) Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 15(1):3–12. https://doi.org/10.1038/sj.cdd.4402269

    Article  CAS  PubMed  Google Scholar 

  4. Garg AD, Vandenberk L, Koks C, Verschuere T, Boon L, Van Gool SW, Agostinis P (2016) Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med 8(328):328–327. https://doi.org/10.1126/scitranslmed.aae0105

    Article  CAS  Google Scholar 

  5. Montico B, Lapenta C, Ravo M, Martorelli D, Muraro E, Zeng B, Comaro E, Spada M, Donati S, Santini SM, Tarallo R, Giurato G, Rizzo F, Weisz A, Belardelli F, Dolcetti R, Dal Col J (2017) Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy. Oncoimmunology 6(11):e1356964. https://doi.org/10.1080/2162402X.2017.1356964

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P (2010) Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 1805(1):53–71. https://doi.org/10.1016/j.bbcan.2009.08.003

    Article  CAS  PubMed  Google Scholar 

  7. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buque A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L (2014) Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3(9):e955691. https://doi.org/10.4161/21624011.2014.955691

    Article  PubMed  PubMed Central  Google Scholar 

  8. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJ (2002) Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169(1):350–358

    Article  CAS  Google Scholar 

  9. Delamarre L, Couture R, Mellman I, Trombetta ES (2006) Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med 203(9):2049–2055. https://doi.org/10.1084/jem.20052442

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES (2005) Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307(5715):1630–1634. https://doi.org/10.1126/science.1108003

    Article  CAS  PubMed  Google Scholar 

  11. Monaco JJ (1995) Pathways for the processing and presentation of antigens to T cells. J Leukoc Biol 57(4):543–547

    Article  CAS  Google Scholar 

  12. Nencioni A, Grunebach F, Schmidt SM, Muller MR, Boy D, Patrone F, Ballestrero A, Brossart P (2008) The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 65(3):191–199. https://doi.org/10.1016/j.critrevonc.2007.10.002

    Article  PubMed  Google Scholar 

  13. Palucka AK, Ueno H, Fay J, Banchereau J (2008) Dendritic cells: a critical player in cancer therapy? J Immunother 31(9):793–805. https://doi.org/10.1097/CJI.0b013e31818403bc

    Article  PubMed  PubMed Central  Google Scholar 

  14. Popescu I, Macedo C, Zeevi A, Nellis J, Patterson KR, Logar A, Rowe D, Reyes J, Rao AS, Storkus WJ, Fung JJ, Metes D (2003) Ex vivo priming of naive T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. Am J Transplant 3(11):1369–1377

    Article  CAS  Google Scholar 

  15. Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R (2003) Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 171(11):5940–5947

    Article  CAS  Google Scholar 

  16. Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G (2013) A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 19(17):4801–4815. https://doi.org/10.1158/1078-0432.CCR-13-1185

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hatfield P, Merrick AE, West E, O'Donnell D, Selby P, Vile R, Melcher AA (2008) Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J Immunother 31(7):620–632. https://doi.org/10.1097/CJI.0b013e31818213df

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kim HS, Choo YS, Koo T, Bang S, Oh TY, Wen J, Song SY (2006) Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer. Immunol Lett 103(2):142–148. https://doi.org/10.1016/j.imlet.2005.10.021

    Article  CAS  PubMed  Google Scholar 

  19. Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW (2015) Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Front Immunol 6:663. https://doi.org/10.3389/fimmu.2015.00663

    Article  CAS  PubMed  Google Scholar 

  20. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F (2000) Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191(10):1777–1788

    Article  CAS  Google Scholar 

  21. Lapenta C, Donati S, Spadaro F, Castaldo P, Belardelli F, Cox MC, Santini SM (2016) NK cell activation in the antitumor response induced by IFN-alpha dendritic cells loaded with apoptotic cells from follicular lymphoma patients. J Immunol 197(3):795–806. https://doi.org/10.4049/jimmunol.1600262

    Article  CAS  PubMed  Google Scholar 

  22. Lapenta C, Santini SM, Spada M, Donati S, Urbani F, Accapezzato D, Franceschini D, Andreotti M, Barnaba V, Belardelli F (2006) IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol 36(8):2046–2060. https://doi.org/10.1002/eji.200535579

    Article  CAS  PubMed  Google Scholar 

  23. Spadaro F, Lapenta C, Donati S, Abalsamo L, Barnaba V, Belardelli F, Santini SM, Ferrantini M (2012) IFN-alpha enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 119(6):1407–1417. https://doi.org/10.1182/blood-2011-06-363564

    Article  CAS  PubMed  Google Scholar 

  24. Dauer M, Schad K, Junkmann J, Bauer C, Herten J, Kiefl R, Schnurr M, Endres S, Eigler A (2006) IFN-alpha promotes definitive maturation of dendritic cells generated by short-term culture of monocytes with GM-CSF and IL-4. J Leukoc Biol 80(2):278–286. https://doi.org/10.1189/jlb.1005592

    Article  CAS  PubMed  Google Scholar 

  25. Dal Col J, Mastorci K, Fae DA, Muraro E, Martorelli D, Inghirami G, Dolcetti R (2012) Retinoic acid/alpha-interferon combination inhibits growth and promotes apoptosis in mantle cell lymphoma through Akt-dependent modulation of critical targets. Cancer Res 72(7):1825–1835. https://doi.org/10.1158/0008-5472.CAN-11-2505

    Article  CAS  PubMed  Google Scholar 

  26. Guidoboni M, Zancai P, Cariati R, Rizzo S, Dal Col J, Pavan A, Gloghini A, Spina M, Cuneo A, Pomponi F, Bononi A, Doglioni C, Maestro R, Carbone A, Boiocchi M, Dolcetti R (2005) Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res 65(2):587–595

    CAS  PubMed  Google Scholar 

  27. Mastorci K, Montico B, Fae DA, Sigalotti L, Ponzoni M, Inghirami G, Dolcetti R, Dal Col J (2016) Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma. Oncotarget 7(27):41913–41928. https://doi.org/10.18632/oncotarget.9630

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Surgery and Dentistry ‘Scuola Medica Salernitana’, University of Salerno, Baronissi, Salerno, Italy

    Annunziata Nigro, Vincenzo Casolaro & Jessica Dal Col

  2. Immunopathology and Cancer Biomarkers Unit, Department of Translational Research, CRO National Cancer Institute – IRCCS, Aviano, Pordenone, Italy

    Barbara Montico

Authors
  1. Annunziata Nigro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Montico
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincenzo Casolaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jessica Dal Col
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jessica Dal Col .

Editor information

Editors and Affiliations

  1. Departamento de Biología Funcional, Inmunología, Universidad de Oviedo, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Oviedo, Spain

    Alejandro López-Soto

  2. Departamento de Bioquímica y Biología Molecular, Universidad de Oviedo, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Oviedo, Asturias, Spain

    Alicia R. Folgueras

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Nigro, A., Montico, B., Casolaro, V., Dal Col, J. (2019). A Novel Dendritic Cell-Based Vaccination Protocol to Stimulate Immunosurveillance of Aggressive Cancers. In: López-Soto, A., Folgueras, A. (eds) Cancer Immunosurveillance. Methods in Molecular Biology, vol 1884. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8885-3_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-8885-3_22

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-8884-6

  • Online ISBN: 978-1-4939-8885-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation